

## 740 Y-P

<b>Cat. No.:</b>	HY-P0175	
<b>CAS No.:</b>	1236188-16-1	
<b>Molecular Formula:</b>	C <sub>141</sub> H <sub>222</sub> N <sub>43</sub> O <sub>39</sub> PS <sub>3</sub>	
<b>Molecular Weight:</b>	3270.7	RQIKIWFQNRMMKWKSDGG-(PO2-Tyr)-MDMS
<b>Sequence Shortening:</b>	RQIKIWFQNRMMKWKSDGG-{PO2Y}-MDMS	
<b>Target:</b>	PI3K; Autophagy	
<b>Pathway:</b>	PI3K/Akt/mTOR; Autophagy	
<b>Storage:</b>	Protect from light	
	Powder    -80°C    2 years	
	-20°C    1 year	
	* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)	

### SOLVENT & SOLUBILITY

<b>In Vitro</b>	DMSO : 25 mg/mL (7.64 mM; Need ultrasonic)																					
	H <sub>2</sub> O : 2 mg/mL (0.61 mM; Need ultrasonic)																					
	<table border="1"> <thead> <tr> <th rowspan="2">Solvent</th> <th rowspan="2">Mass</th> <th colspan="3">Concentration</th> </tr> <tr> <th>1 mg</th> <th>5 mg</th> <th>10 mg</th> </tr> </thead> <tbody> <tr> <td rowspan="4">Preparing Stock Solutions</td> <td>1 mM</td> <td>0.3057 mL</td> <td>1.5287 mL</td> <td>3.0574 mL</td> </tr> <tr> <td>5 mM</td> <td>0.0611 mL</td> <td>0.3057 mL</td> <td>0.6115 mL</td> </tr> <tr> <td>10 mM</td> <td>---</td> <td>---</td> <td>---</td> </tr> </tbody> </table>	Solvent	Mass	Concentration			1 mg	5 mg	10 mg	Preparing Stock Solutions	1 mM	0.3057 mL	1.5287 mL	3.0574 mL	5 mM	0.0611 mL	0.3057 mL	0.6115 mL	10 mM	---	---	---
	Solvent			Mass	Concentration																	
		1 mg	5 mg		10 mg																	
Preparing Stock Solutions	1 mM	0.3057 mL	1.5287 mL	3.0574 mL																		
	5 mM	0.0611 mL	0.3057 mL	0.6115 mL																		
	10 mM	---	---	---																		
	Please refer to the solubility information to select the appropriate solvent.																					
<b>In Vivo</b>	<ol style="list-style-type: none"> <li>Add each solvent one by one: 10% DMSO &gt;&gt; 40% PEG300 &gt;&gt; 5% Tween-80 &gt;&gt; 45% saline Solubility: ≥ 2.5 mg/mL (0.76 mM); Clear solution</li> <li>Add each solvent one by one: 10% DMSO &gt;&gt; 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (0.76 mM); Clear solution</li> <li>Add each solvent one by one: 10% DMSO &gt;&gt; 90% corn oil Solubility: ≥ 2.5 mg/mL (0.76 mM); Clear solution</li> </ol>																					

### BIOLOGICAL ACTIVITY

<b>Description</b>	740 Y-P (740YPDGFR; PDGFR 740Y-P) is a potent and cell-permeable PI3K activator. 740 Y-P readily binds GST fusion proteins containing both the N- and C- terminal SH2 domains of p85 but fails to bind GST alone <sup>[1]</sup> .
<b>IC<sub>50</sub> &amp; Target</b>	PI3K

## In Vitro

740 Y-P (50 µg/mL; 48 hours) specifically stimulates mitogenesis in medium is better than EGF or FGF at stimulating entry into S-phase, it shows the percentage of cells in S-phase for 48.3% in C2 cells. Additionally, LY294002 (HY-10108) or Wortmannin (HY-10197) potently inhibits the mitogenic response stimulated by the peptide<sup>[1]</sup>.

740 Y-P (1 µg/mL) stimulates mitogenesis at the lowest concentration tested. The peptide stimulates mitogenesis in both the presence and absence of serum (0.5%), and in the former instance a maximal response observed at 50 µg/mL. 740Y-P to stimulate mitogenesis is highly specific and not a general feature of a cell permeable SH2 domain binding peptides<sup>[1]</sup>.

740 Y-P (30 µM; 24 hours) remarkably inhibits the level of LC3-II/LC3-I in GO-induced PC12 cells<sup>[2]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis<sup>[2]</sup>

Cell Line:	PC12 cells
Concentration:	30 µM
Incubation Time:	24 hours
Result:	Inhibited the protein expression of LC3-II.

## In Vivo

740 Y-P is not only internalised in living cells but can also interact with p85 in vivo<sup>[1]</sup>.

740 Y-P (intraperitoneal injection; 10 mg/kg; 6 weeks) decreases the degree of ROS levels in Aβ(25-32) treated hippocampal tissues and increases the extent of AKT and PI3K phosphorylation in alzheimer's disease (AD) rat model<sup>[3]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## CUSTOMER VALIDATION

- Biomaterials. 2019 Feb;194:57-72.
- Acta Biomater. 2018 Nov;81:278-292.
- J Exp Clin Cancer Res. 2021 Aug 12;40(1):255.
- J Exp Clin Cancer Res. 2020 Jun 30;39(1):123.
- Oxid Med Cell Longev. 2021 Mar 31.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

## REFERENCES

[1]. Derossi D, et al. Stimulation of mitogenesis by a cell-permeable PI 3-kinase binding peptide.

[2]. Xiaoli Feng, et al. Graphene Oxide Induces p62/SQSTM-dependent Apoptosis Through the Impairment of Autophagic Flux and Lysosomal Dysfunction in PC12 Cells. Acta Biomater. 2018 Nov;81:278-292.

[3]. Zhiqing Sun, et al. GABAB Receptor-Mediated PI3K/Akt Signaling Pathway Alleviates Oxidative Stress and Neuronal Cell Injury in a Rat Model of Alzheimer's Disease. J Alzheimers Dis. 2020;76(4):1513-1526.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

India Contact:  
Life Technologies (India) Pvt. Ltd.  
306, Aggarwal City Mall, Opposite M2K Pitampura, Delhi – 110034 (INDIA). Ph: +91-11-42208000, 42208111, 42208222, Mobile: +91-9810521400, Fax: +91-11-42208444  
Email: [customerservice@lifetechindia.com](mailto:customerservice@lifetechindia.com) Website: [www.lifetechindia.com](http://www.lifetechindia.com)